Overview

A Dose Escalation and Expansion Trial With BYON4228 Alone and in Combination in Patients With Advanced or Metastatic Solid Tumors

Status:
RECRUITING

Trial end date:
2027-09-01

Target enrollment:

Participant gender:

Summary

This is a phase I trial with BYON4228, a humanized monoclonal antibody (mAb) directed against signal regulatory protein (SIRP) in solid tumors, alone and in combination with pembrolizumab.

Phase:

PHASE1

Details

Lead Sponsor:

Byondis B.V.

Treatments:

pembrolizumab